Dr. Reddy's Laboratories has launched Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the US Food and Drug Administration (USFDA).
The Zyban brand and generic had US sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health. Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: